Roth Capital Issues Positive Forecast for MGRM Earnings

Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Free Report) - Research analysts at Roth Capital upped their Q1 2025 earnings estimates for shares of Monogram Orthopaedics in a report issued on Thursday, March 13th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per share of ($0.10) for the quarter, up from their prior forecast of ($0.11). The consensus estimate for Monogram Orthopaedics' current full-year earnings is ($0.49) per share. Roth Capital also issued estimates for Monogram Orthopaedics' Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($0.70) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($0.63) EPS and FY2027 earnings at ($0.24) EPS.

Separately, Roth Mkm lifted their target price on shares of Monogram Orthopaedics from $4.00 to $5.40 and gave the company a "buy" rating in a report on Tuesday.

Monogram Orthopaedics Trading Down 8.9 %

Monogram Orthopaedics stock traded down $0.30 during trading on Monday, hitting $3.06. The company had a trading volume of 239,614 shares, compared to its average volume of 288,256. Monogram Orthopaedics has a 1-year low of $1.53 and a 1-year high of $4.90. The company's 50 day simple moving average is $2.60 and its 200-day simple moving average is $2.50. The stock has a market cap of $107.98 million, a price-to-earnings ratio of -6.49 and a beta of 1.66.

Remove Ads

Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) last posted its earnings results on Wednesday, March 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03.

Hedge Funds Weigh In On Monogram Orthopaedics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new position in Monogram Orthopaedics in the 4th quarter valued at approximately $25,000. Wells Fargo & Company MN boosted its position in Monogram Orthopaedics by 286.6% in the 4th quarter. Wells Fargo & Company MN now owns 11,597 shares of the company's stock valued at $27,000 after buying an additional 8,597 shares during the period. Barclays PLC purchased a new position in Monogram Orthopaedics in the 3rd quarter valued at approximately $29,000. Orion Portfolio Solutions LLC purchased a new stake in shares of Monogram Orthopaedics during the 4th quarter worth $31,000. Finally, State Street Corp purchased a new stake in shares of Monogram Orthopaedics during the 3rd quarter worth $62,000. Hedge funds and other institutional investors own 0.45% of the company's stock.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.